
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
p>GlaxoSmithKline has filed a supplemental new drug application with the FDA for dutasteride (Avodart) for prostate cancer risk reduction among men at increased risk of developing the disease.
GlaxoSmithKline has filed a supplemental new drug application with the FDA for dutasteride (Avodart) for prostate cancer risk reduction among men at increased risk of developing the disease.
European Union filings also are under way via the European Mutual Recognition Variation Procedure, with Sweden acting as the Reference Member State.
Dutasteride is not currently approved or licensed to treat or reduce the risk of prostate cancer.





